RxDoctor Payments Data

Katherine Abbo, MD

Cardiovascular Disease · Kenosha, WINPI 1962488965

Payments from drug & device makers

$2,573in general payments, 2019–2025

Across 148 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$529
  • AstraZeneca$369
  • Pfizer$228
  • Novo Nordisk$202
  • Boehringer Ingelheim$194
  • Amgen$177
  • plus $875 from 14 others

What the payments were for

  • Food & beverage$2,39893%
  • Education$1757%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,573 in reported general payments places this provider in the 60th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$137,338
Medicare patients
456
Services billed
1,284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban431$435,874
EntrestoSacubitril/Valsartan69$66,902
JardianceEmpagliflozin53$50,873
Repatha SureclickEvolocumab37$32,138
XareltoRivaroxaban22$29,028
Metoprolol Succinate507$6,568
Amiodarone Hcl78$6,020
ClopidogrelClopidogrel Bisulfate384$4,249
Diltiazem 24hr Er (Cd)Diltiazem Hcl119$3,539
Potassium Chloride217$3,479
Atorvastatin Calcium247$2,415
Carvedilol202$2,028
Losartan Potassium192$2,013
Colchicine19$1,911
Rosuvastatin Calcium192$1,803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$228$435,874431 claims
NovartisEntresto$105$66,90269 claims
Boehringer IngelheimJardiance$194$50,87353 claims
Johnson & JohnsonXarelto$85$29,02822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Kenosha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →